



1 December 2017

ASX ANNOUNCEMENT

San Antonio Breast Cancer Symposium L-Dex® Abstracts Released

Brisbane, Australia and Carlsbad, Calif.- ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status, is pleased to announce that four new abstracts have been released containing data from independent clinical studies, and will be presented at the San Antonio Breast Cancer Symposium 7th and 9th December 2017. The Symposium is the world's largest breast cancer meeting and has over 7,000 clinicians from across the globe in attendance.

Combined, these studies prospectively followed more than 1,100 patients with L-Dex and the results continue to show the clinical value of earlier detection of lymphoedema using L-Dex. Across all studies, there was a significant reduction in the number of patients who went on to develop later stage lymphoedema.

These new studies further support the value of prospective surveillance using L-Dex for the early detection of subclinical lymphoedema and subsequent reduction in chronic breast cancer related lymphoedema (BCRL) rates.

The four abstracts are available online:

1. Whitworth P, Cooper A, Shah C, Vicini F. The impact of a structured surveillance protocol using bioimpedance spectroscopy (BIS) on preventing breast cancer related lymphedema (BCRL) in high-risk patients. SABCS P3-14-08.
http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_583
2. Kaufman D, Shah C, Vicini F. Low rates of chronic breast cancer related lymphedema (BCRL) in a cohort of high-risk patients undergoing prospective surveillance with bioimpedance spectroscopy (BIS). SABCS P3-14-09
http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_584
3. Kaufman D, Shah C, Vicini F. Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer related lymphedema. SABCS P6-12-03
http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_42
4. Koelmeyer LA, Borotkanics R, Winch CJ, Prah P, Alcorso JM, Nakhel K, Boyages J. L-Dex® surveillance of breast cancer-related lymphoedema: a retrospective study. SABCS P6-12-16
http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_1497

"We are very pleased to continue to see further evidence that using L-Dex for early detection of BCRL shows improved outcomes for cancer survivors around the world," said Richard Carreon, Managing Director and CEO of ImpediMed.

The University of Texas Health San Antonio Cancer Center, the American Association for Cancer Research, and Baylor College of Medicine will be hosting the 2017 San Antonio Breast Cancer Symposium, 5th – 9th Dec, at the Henry B. Gonzalez Convention Center. The symposium provides news on state-of-the-art breast cancer research, including experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease. This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate health care professionals.

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contact:

Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex[®] device. In addition, ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[™], sold in select markets globally.

For more information, visit www.impedimed.com.